David Planchard

51.0k total citations · 10 hit papers
431 papers, 16.5k citations indexed

About

David Planchard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Planchard has authored 431 papers receiving a total of 16.5k indexed citations (citations by other indexed papers that have themselves been cited), including 308 papers in Pulmonary and Respiratory Medicine, 288 papers in Oncology and 81 papers in Molecular Biology. Recurrent topics in David Planchard's work include Lung Cancer Treatments and Mutations (259 papers), Lung Cancer Research Studies (111 papers) and Cancer Immunotherapy and Biomarkers (106 papers). David Planchard is often cited by papers focused on Lung Cancer Treatments and Mutations (259 papers), Lung Cancer Research Studies (111 papers) and Cancer Immunotherapy and Biomarkers (106 papers). David Planchard collaborates with scholars based in France, United States and Spain. David Planchard's co-authors include Benjamin Besse, Egbert F. Smit, Jean‐Charles Soria, Solange Peters, Silvia Novello, Tony Mok, Keith M. Kerr, Julien Mazières, Matthew D. Hellmann and Martin Reck and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

David Planchard

411 papers receiving 16.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2018 1.6k citations David Planchard, Sanjay Popat et al. Annals of Oncology profile →
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Pasi A. Jänne, James Chih‐Hsin Yang et al. profile →
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

2017 948 citations David Planchard, Benjamin Besse et al. profile →
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

2018 712 citations Laura Mezquita, Édouard Auclin et al. Journal of Clinical Oncology profile →
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2016 612 citations David Planchard, Benjamin Besse et al. profile →
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 370 citations Tony Mok, Antonio Passaro et al. Annals of Oncology profile →
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

2016 334 citations David Planchard, Fabrice Barlési et al. profile →
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

2019 305 citations Ki Hyeong Lee, Byoung Chul Cho et al. Journal of Thoracic Oncology profile →
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 286 citations Tony Mok, Antonio Passaro et al. Annals of Oncology profile →
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Enriqueta Felip, Luis Paz‐Ares et al. profile →

Peers

Countries citing papers authored by David Planchard

Since Specialization

Citations

This map shows the geographic impact of David Planchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Planchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Planchard more than expected).

Fields of papers citing papers by David Planchard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Planchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Planchard. The network helps show where David Planchard may publish in the future.

Co-authorship network of co-authors of David Planchard

This figure shows the co-authorship network connecting the top 25 collaborators of David Planchard. A scholar is included among the top collaborators of David Planchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Planchard. David Planchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NTRK gene fusion testing and management in lung cancer 2024 ·Cancer Treatment Reviews ·Matteo Repetto, Marina Chiara Garassino, Herbert H. Loong, Fernando López‐Ríos, Tony Mok, Solange Peters, David Planchard, Sanjay Popat, Erin R. Rudzinski, Alexander Drilon, Caicun Zhou	7
2	Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors 2024 ·ESMO Open ·(unknown), Han Zeng, Qi Chen, Shanjun Tan, Qi Huang, (unknown), Wei Li, David Planchard, Panwen Tian	2
3	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	0
4	The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat? 2024 ·Cancer Research and Treatment ·Mariona Riudavets, David Planchard	1
5	ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. 2024 ·Journal of Clinical Oncology ·David Planchard, Nathalie Cozic, Marie Wislez, C. Chouaïd, (unknown), Sophie Cousin, Céline Mascaux, Jacques Cadranel, Margaux Geier, Maria‐Rosa Ghigna, (unknown), Ricardo Zwirtes, Rachel Chiaverelli, (unknown), (unknown), Fernanda Mosele, Fabrice André, Guillaume Montagnac, Barbara Pistilli	6
6	Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Pierre Decazes, Samy Ammari, (unknown), (unknown), (unknown), (unknown), Hugues Talbot, Siham Farhane, Paul-Henry Cournède, Aurélien Marabelle, Florian Guisier, David Planchard, Tony Ibrahim, Caroline Robert, Fabrice Barlési, Pierre Véra, Nathalie Lassau	9
7	80P Tumor microenvironment (TME) defines prognosis of EGFR-mutant non-small cell lung cancer (NSCLC) 2023 ·ESMO Open ·Lodovica Zullo, Maria‐Rosa Ghigna, (unknown), (unknown), Damien Vasseur, Maxime Frélaut, (unknown), Marco Tagliamento, (unknown), Anas Gazzah, Luc Friboulet, J-Y. Scoazec, Jordi Remón, Fabrice Barlési, Benjamin Besse, David Planchard, Mihaela Aldea	1
8	2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC 2023 ·Annals of Oncology ·(unknown), Maria‐Rosa Ghigna, Filippo Gustavo Dall’Olio, Martina Mandarano, Alessandro Russo, Judith Raimbourg, Safae Terrisse, Giulio Metro, Anas Gazzah, Fabrice Barlési, J. Remon Masip, David Planchard, Benjamin Besse, Mihaela Aldea	1
9	1456P Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Lodovica Zullo, Mihaela Aldea, (unknown), (unknown), V. Fontana, (unknown), Davide Soldato, (unknown), (unknown), Giuseppe Barletta, Chiara Dellepiane, Giovanni Rossi, (unknown), (unknown), Claudia Parisi, Lucia Del Mastro, David Planchard, Rossana Berardi, Benjamin Besse, Carlo Genova	1
10	LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Hossein Borghaei, Melissa L. Johnson, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Daphne W. Dumoulin, Filippo de Marinis, Charles H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, (unknown), (unknown), Ronald Shazer, Xin Yan, (unknown), (unknown)	4
11	512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC 2023 ·Annals of Oncology ·David Planchard, Pasi A. Jänne, Ying Cheng, Chee Khoon Lee, К. К. Лактионов, (unknown), Yan Yu, Terufumi Kato, Lingxiang Jiang, (unknown), Sarayut Lucien Geater, (unknown), (unknown), Libor Havel, Frances A. Shepherd, Kentaro Tanaka, Dana Ghiorghiu, Edgar Monterroso, (unknown), James Chih‐Hsin Yang	0
12	Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial 2023 ·British Journal of Cancer ·Sophie Postel‐Vinay, (unknown), Matthieu Texier, Mihaela Aldea, Anas Gazzah, Manuel Dómine, David Planchard, R. de las Peñas, (unknown), Santiago Viteri, (unknown), Ana Laura Ortega Granados, Teresa Morán, Carlos Camps, Ana López, Mariano Provencio, Jean‐Charles Soria, Benjamin Besse, Bartomeu Massutí, Rafael Rosell	4
13	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study 2022 ·Cancers ·R. Descourt, M. Pérol, (unknown), David Planchard, B. Mennecier, Marie Wislez, Jacques Cadranel, Alexis B. Cortot, Florian Guisier, Loïck Galland, Pascal Dô, Roland Schött, Éric Dansin, Jennifer Arrondeau, J.B. Auliac, Margaux Geier, C. Chouaïd	5
14	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study 2021 ·Lung Cancer ·Nicolas Epaillard, José Carlos Benítez, (unknown), Elizabeth Fabre, Mariona Riudavets, Roxana Reyes, David Planchard, Stéphane Oudard, Núria Viñolas, Noemı́ Reguart, Benjamin Besse, Laura Mezquita, Édouard Auclin	12
15	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Helena A. Yu, Luis Paz‐Ares, James Chih‐Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard	31
16	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearranged Non–Small-Cell Lung Cancer 2019 ·Clinical Cancer Research ·Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Laura Mezquita, Mélanie Laporte, Aurélie Honoré, Yann Lécluse, (unknown), Maud Ngo‐Camus, Claudio Nicotra, Jordi Remón, Ludovic Lacroix, David Planchard, Luc Friboulet, Benjamin Besse, Françoise Farace	92
17	Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non–Small Cell Lung Cancer Patients 2017 ·Cancer Research ·Emma Pailler, Marianne Oulhen, Isabelle Borget, Jordi Remón, (unknown), Nathalie Auger, Fanny Billiot, Maud Ngo Camus, Frédéric Commo, Colin R. Lindsay, David Planchard, Jean‐Charles Soria, Benjamin Besse, Françoise Farace	59
18	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial 2017 ·Journal of Clinical Oncology ·Federica Grosso, Nicola Steele, Silvia Novello, Anna K. Nowak, Sanjay Popat, Laurent Greillier, Thomas John, Natasha B. Leighl, Martin Reck, Paul Taylor, David Planchard, Jens Benn Sørensen, Mark A. Socinski, Ute von Wangenheim, (unknown), José Barrueco, Nassim Morsli, Giorgio V. Scagliotti	77
19	Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1 - and ALK -Rearranged Lung Cancers 2016 ·Clinical Cancer Research ·Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, Linda Mahjoubi, Ludovic Lacroix, David Planchard, Benjamin Besse, Françoise Farace, Nathalie Auger, Jordi Remón, Jean‐Yves Scoazec, Fabrice André, Jean‐Charles Soria, Luc Friboulet	111
20	Second-line therapy in patients with malignant pleural mesothelioma. French retrospective study 2005-2006 2011 ·European Respiratory Journal ·J. Margery, Pierre Ruffiè, F. Rivière, David Planchard, H. Le Floch, (unknown), Benjamin Besse, F. Vaylet	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact